{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T07:20:08Z","timestamp":1784704808101,"version":"3.55.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"The Netherlands Organization for Health Research and Development","doi-asserted-by":"crossref","award":["522004005"],"award-info":[{"award-number":["522004005"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"crossref"}]},{"name":"ECTMIH 2023","award":["474"],"award-info":[{"award-number":["474"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Hepatitis A (hepA) vaccination is highly immunogenic in healthy individuals; however, there is uncertainty about the immunogenicity in immunocompromised populations (ICPs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this prospective cohort study, people living with HIV (PLWH), patients on immunosuppressive mono- and combination therapy, and controls received two hepA vaccine doses at months 0 and 6\u201312, or three combined hepA\/B vaccine doses at months 0, 1 and 6\u201312. Antibody levels were measured before and at different time-points post-vaccination (T2, 6, 8, 12\u00a0months). The primary endpoint was the seroconversion rate (SCR) at T8, defined as hepA antibodies \u226520 mIU\/ml. To assess boostability, an additional vaccine dose was administered 1\u20135\u00a0years after T12 in those with antibodies &amp;lt;\u200950 mIU\/ml, with antibody measurements before and seven days after the booster dose.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 150 participants. At T2 SCRs ranged between 35\u201358% in ICPs versus 94% in controls. Among PLWH, patients on monotherapy, combination therapy and controls SCRs at T8 were 33\/34 (97%), 32\/34 (94%), 25\/30 (83%) and 28\/28 (100%), respectively. The booster dose resulted in 71% additional seroconversion (17\/24), with only patients using combination therapy not responding.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>HepA vaccination is highly immunogenic in virologically suppressed PLWH and patients on immunosuppressive monotherapy, with SCRs after the complete hepA vaccination schedule similar to controls and adequate booster responses in case of waning immunity. However, patients using immunosuppressive combination therapy as well as all ICPs who did not receive the complete hepA vaccination schedule, are at risk of non-response to vaccination and post-vaccination antibody measurements are recommended.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jtm\/taae125","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:08:01Z","timestamp":1726099681000},"source":"Crossref","is-referenced-by-count":11,"title":["Hepatitis a vaccine immunogenicity and boostability in adults receiving immunosuppressive therapy and adults living with HIV: a prospective single-centre cohort study"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2691-8130","authenticated-orcid":false,"given":"Jenny L","family":"Schnyder","sequence":"first","affiliation":[{"name":"Centre of Tropical Medicine and Travel Medicine , Department of Infectious Diseases, Division of Internal Medicine, Amsterdam UMC, , Meibergdreef 9, 1105 AZ Amsterdam,","place":["the Netherlands"]},{"name":"Location University of Amsterdam , Department of Infectious Diseases, Division of Internal Medicine, Amsterdam UMC, , Meibergdreef 9, 1105 AZ Amsterdam,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2244-9031","authenticated-orcid":false,"given":"Hannah M","family":"Garcia Garrido","sequence":"additional","affiliation":[{"name":"Centre of Tropical Medicine and Travel Medicine , Department of Infectious Diseases, Division of Internal Medicine, Amsterdam UMC, , Meibergdreef 9, 1105 AZ Amsterdam,","place":["the Netherlands"]},{"name":"Location University of Amsterdam , Department of Infectious Diseases, Division of Internal Medicine, Amsterdam UMC, , Meibergdreef 9, 1105 AZ Amsterdam,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W","family":"Tanck","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Data Science , Amsterdam UMC, , Meibergdreef 9, 1105 AZ Amsterdam,","place":["the Netherlands"]},{"name":"Location University of Amsterdam , Amsterdam UMC, , Meibergdreef 9, 1105 AZ Amsterdam,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma","family":"Maurer","sequence":"additional","affiliation":[{"name":"Department of Experimental Immunology , Amsterdam Institute for Infection and Immunity, Amsterdam UMC, , Meibergdreef 9, 1105 AZ Amsterdam,","place":["the Netherlands"]},{"name":"Location University of Amsterdam , Amsterdam Institute for Infection and Immunity, Amsterdam UMC, , Meibergdreef 9, 1105 AZ Amsterdam,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes M","family":"Harskamp","sequence":"additional","affiliation":[{"name":"Department of Experimental Immunology , Amsterdam Institute for Infection and Immunity, Amsterdam UMC, , Meibergdreef 9, 1105 AZ Amsterdam,","place":["the Netherlands"]},{"name":"Location University of Amsterdam , Amsterdam Institute for Infection and Immunity, Amsterdam UMC, , Meibergdreef 9, 1105 AZ Amsterdam,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeltje","family":"Kootstra","sequence":"additional","affiliation":[{"name":"Department of Experimental Immunology , Amsterdam Institute for Infection and Immunity, Amsterdam UMC, , Meibergdreef 9, 1105 AZ Amsterdam,","place":["the Netherlands"]},{"name":"Location University of Amsterdam , Amsterdam Institute for Infection and Immunity, Amsterdam UMC, , Meibergdreef 9, 1105 AZ Amsterdam,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin P","family":"Grobusch","sequence":"additional","affiliation":[{"name":"Centre of Tropical Medicine and Travel Medicine , Department of Infectious Diseases, Division of Internal Medicine, Amsterdam UMC, , Meibergdreef 9, 1105 AZ Amsterdam,","place":["the Netherlands"]},{"name":"Location University of Amsterdam , Department of Infectious Diseases, Division of Internal Medicine, Amsterdam UMC, , Meibergdreef 9, 1105 AZ Amsterdam,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Goorhuis","sequence":"additional","affiliation":[{"name":"Centre of Tropical Medicine and Travel Medicine , Department of Infectious Diseases, Division of Internal Medicine, Amsterdam UMC, , Meibergdreef 9, 1105 AZ Amsterdam,","place":["the Netherlands"]},{"name":"Location University of Amsterdam , Department of Infectious Diseases, Division of Internal Medicine, Amsterdam UMC, , Meibergdreef 9, 1105 AZ Amsterdam,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"key":"2025031205242603900_ref1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2310\/7060.2004.13633","article-title":"Travel patterns and risk behavior in solid organ transplant recipients","volume":"11","author":"Boggild","year":"2004","journal-title":"J Travel Med"},{"key":"2025031205242603900_ref2","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taad153","article-title":"Liver transplantation due to fulminant hepatitis a in a traveller visiting friends and relatives in Comoros","volume":"31","author":"Diallo","year":"2024","journal-title":"J Travel Med"},{"key":"2025031205242603900_ref3","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taz034","article-title":"Travel vaccination recommendations and infection risk in HIV-positive travellers","volume":"26","author":"Chang","year":"2019","journal-title":"J Travel Med"},{"key":"2025031205242603900_ref4","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taac013","article-title":"Acute hepatitis a in international travellers: a GeoSentinel analysis, 2008\u20132020","volume":"29","author":"Balogun","year":"2022","journal-title":"J Travel Med"},{"key":"2025031205242603900_ref5","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taad085","article-title":"Travel vaccines\u2014priorities determined by incidence and impact","volume":"30","author":"Steffen","year":"2023","journal-title":"J Travel Med"},{"key":"2025031205242603900_ref6","first-page":"1","article-title":"Prevention of hepatitis a virus infection in the United States: recommendations of the advisory committee on immunization practices, 2020","volume":"69","author":"Nelson","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025031205242603900_ref7","first-page":"493","article-title":"WHO position paper on hepatitis a vaccines\u2013October 2022","volume":"97","author":"World Health Organization","year":"2022","journal-title":"Wkly Epidemiol Rec"},{"key":"2025031205242603900_ref8","volume-title":"WHO Immunological Basis for Immunization Series, Module 18: Hepatitis A Update","author":"World Health Organization","year":"2019"},{"key":"2025031205242603900_ref9","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1093\/infdis\/jiv060","article-title":"Response to hepatitis a vaccination in immunocompromised travelers","volume":"212","author":"Garcia Garrido","year":"2015","journal-title":"J Infect Dis"},{"key":"2025031205242603900_ref10","doi-asserted-by":"crossref","first-page":"101479","DOI":"10.1016\/j.tmaid.2019.101479","article-title":"Hepatitis a vaccine immunogenicity in patients using immunosuppressive drugs: a systematic review and meta-analysis","volume":"32","author":"Garrido","year":"2019","journal-title":"Travel Med Infect Dis"},{"key":"2025031205242603900_ref11","doi-asserted-by":"crossref","first-page":"328","DOI":"10.15585\/mmwr.mm6814a3","article-title":"Notes from the field: acute hepatitis a virus infection among previously vaccinated persons with HIV infection\u2014Tennessee, 2018","volume":"68","author":"Brennan","year":"2019","journal-title":"MMWR Morb Mortal Wkly"},{"key":"2025031205242603900_ref12","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s15010-018-1129-1","article-title":"A case of acute hepatitis a infection in an HIV-positive patient despite complete hepatitis a vaccination","volume":"46","author":"Fritzsche","year":"2018","journal-title":"Infection"},{"key":"2025031205242603900_ref13","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1258\/ijsa.2010.010269","article-title":"A case of hepatitis a vaccination failure in an HIV-positive man who had sex with men in Israel","volume":"23","author":"Mor","year":"2012","journal-title":"Int J STD AIDS"},{"key":"2025031205242603900_ref14","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jiac.2018.01.020","article-title":"Transfusion transmission of hepatitis a virus with fecal shedding in a previously hepatitis a vaccinated recipient","volume":"24","author":"Vestergaard","year":"2018","journal-title":"J Infect Chemother"},{"key":"2025031205242603900_ref15","article-title":"Low rate of vaccination and risk of incident hepatitis a among HIV-infected men who have sex with men in Seville, southern Spain","volume":"42","author":"Fernandez-Fuertes","year":"2024","journal-title":"Enferm Infecc Microbiol Clin (English ed)"},{"key":"2025031205242603900_ref16","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/00007890-200102150-00023","article-title":"Rapid decline of antibodies after hepatitis a immunization in liver and renal transplant recipients","volume":"71","author":"G\u00fcnther","year":"2001","journal-title":"Transplantation"},{"key":"2025031205242603900_ref17","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/hep.30495","article-title":"Early seroreversion after 2 doses of hepatitis a vaccination in human immunodeficiency virus\u2013positive patients: incidence and associated factors","volume":"70","author":"Huang","year":"2019","journal-title":"Hepatology"},{"key":"2025031205242603900_ref18","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/liv.13665","article-title":"Serological responses to revaccination with hepatitis a virus (HAV) vaccines among HIV-positive individuals whose anti-HAV antibody waned after primary vaccination","volume":"38","author":"Chen","year":"2018","journal-title":"Liver Int"},{"key":"2025031205242603900_ref19","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/clinids\/11.6.954","article-title":"Risk of infectious complications in patients taking glucocorticosteroids","volume":"11","author":"Stuck","year":"1989","journal-title":"Rev Infect Dis"},{"key":"2025031205242603900_ref20","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1086\/318522","article-title":"Randomized, double-blind study in healthy adults to assess the boosting effect of Vaqta or Havrix after a single dose of Havrix","volume":"32","author":"Connor","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2025031205242603900_ref21","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0264-410X(00)00301-7","article-title":"Randomized, cross-over, controlled comparison of two inactivated hepatitis a vaccines","volume":"19","author":"Bryan","year":"2000","journal-title":"Vaccine"},{"key":"2025031205242603900_ref22","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1016\/S0264-410X(01)00195-5","article-title":"A randomised comparison of two inactivated hepatitis a vaccines, Avaxim\u2122 and Vaqta\u2122, given as a booster to subjects primed with Avaxim\u2122","volume":"19","author":"Clarke","year":"2001","journal-title":"Vaccine"},{"key":"2025031205242603900_ref23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1708-8305.1998.tb00450.x","article-title":"Immunogenicity and reactogenicity of Avaxim (160 AU) as compared with Havrix (1440 EL. U) as a booster following primary immunization with Havrix (1440 EL. U) against hepatitis a","volume":"5","author":"Zuckerman","year":"1998","journal-title":"J Travel Med"},{"key":"2025031205242603900_ref24","article-title":"Hepatitis a immunisation in persons not previously exposed to hepatitis a","volume":"12","author":"Irving","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2025031205242603900_ref25","volume-title":"IBM SPSS Statistics for Windows, Version 28.0","author":"IBM Corp","year":"2021"},{"key":"2025031205242603900_ref26","volume-title":"R: A language and environment for statistical computing Vienna","author":"R Core Team","year":"2023"},{"key":"2025031205242603900_ref27","volume-title":"GraphPad Prism, version 9.0.0 for Windows","author":"GraphPad Software Inc"},{"key":"2025031205242603900_ref28","article-title":"Immunogenicity of the 13-Valent pneumococcal conjugate vaccine (PCV13) followed by the 23-Valent pneumococcal polysaccharide vaccine (PPSV23) in adults with and without immunosuppressive therapy","volume":"10","author":"Garcia, Garrido","year":"2022","journal-title":"Vaccine"},{"key":"2025031205242603900_ref29","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/01.MIB.0000437736.91712.a1","article-title":"Efficacy of hepatitis a vaccination and factors impacting on seroconversion in patients with inflammatory bowel disease","volume":"20","author":"Park","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2025031205242603900_ref30","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1086\/315125","article-title":"Immunogenicity and safety of hepatitis a vaccine in liver and renal transplant recipients","volume":"180","author":"Stark","year":"1999","journal-title":"J Infect Dis"},{"key":"2025031205242603900_ref31","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.tmaid.2014.01.005","article-title":"Hepatitis a vaccine for immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-centre study","volume":"12","author":"Askling","year":"2014","journal-title":"Travel Med Infect Dis"},{"key":"2025031205242603900_ref32","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.vaccine.2005.07.102","article-title":"Efficacy of inactivated hepatitis a vaccine in HIV-infected patients: a hierarchical Bayesian meta-analysis","volume":"24","author":"Shire","year":"2006","journal-title":"Vaccine"},{"key":"2025031205242603900_ref33","volume-title":"Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach Geneva","author":"World Health Organization","year":"2006"},{"key":"2025031205242603900_ref34","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/cid\/cix915","article-title":"Global trends in CD4 cell count at the start of antiretroviral therapy: collaborative study of treatment programs","volume":"66","author":"The IeDEA and COHERE Cohort Collaborations","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2025031205242603900_ref35","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jmii.2020.06.014","article-title":"Effectiveness of hepatitis a vaccination among people living with HIV in Taiwan: is one dose enough?","volume":"55","author":"Tsai","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"key":"2025031205242603900_ref36","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.cmi.2023.08.006","article-title":"Coadministered pneumococcal conjugate vaccine decreases immune response to hepatitis a vaccine: a randomized controlled trial","volume":"29","author":"Riekkinen","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"2025031205242603900_ref37","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41572-023-00461-2","article-title":"Hepatitis a virus infection","volume":"9","author":"Van Damme","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"2025031205242603900_ref38","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.1016\/0264-410X(92)90572-2","article-title":"Inactivated hepatitis a vaccine: active and passive immunoprophylaxis in chimpanzees","volume":"10 Suppl 1","author":"Purcell","year":"1992","journal-title":"Vaccine"},{"key":"2025031205242603900_ref39","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1001\/jama.1994.03510410040030","article-title":"Protection against hepatitis a by an inactivated vaccine","volume":"271","author":"Innis","year":"1994","journal-title":"JAMA"},{"key":"2025031205242603900_ref40","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1056\/NEJM199208133270702","article-title":"A controlled trial of a formalin-inactivated hepatitis a vaccine in healthy children","volume":"327","author":"Werzberger","year":"1992","journal-title":"N Engl J Med"},{"key":"2025031205242603900_ref41","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1016\/j.vaccine.2015.06.099","article-title":"A single dose of inactivated hepatitis a vaccine promotes HAV-specific memory cellular response similar to that induced by a natural infection","volume":"33","author":"Melgaco","year":"2015","journal-title":"Vaccine"},{"key":"2025031205242603900_ref42","first-page":"192","volume-title":"Semin Hematol","author":"Haggenburg","year":"2022"},{"key":"2025031205242603900_ref43","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1016\/j.vaccine.2023.04.075","article-title":"Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: a prospective observational cohort study","volume":"41","author":"Ku","year":"2023","journal-title":"Vaccine"},{"key":"2025031205242603900_ref44","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.tmaid.2017.12.004","article-title":"An extra priming dose of hepatitis a vaccine to adult patients with rheumatoid arthritis and drug induced immunosuppression\u2013a prospective, open-label, multi-center study","volume":"21","author":"Rosdahl","year":"2018","journal-title":"Travel Med Infect Dis"},{"key":"2025031205242603900_ref45","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41598-020-80052-3","article-title":"A randomized controlled trial of comparative effectiveness between the 2 dose and 3 dose regimens of hepatitis a vaccine in kidney transplant recipients","volume":"11","author":"Prasoppokakorn","year":"2021","journal-title":"Sci Rep"},{"key":"2025031205242603900_ref46","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/QAI.0b013e318183a9c0","article-title":"Immunological efficacy of a three-dose schedule of hepatitis a vaccine in HIV-infected adults: HEPAVAC study","volume":"49","author":"Launay","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025031205242603900_ref47","first-page":"606","article-title":"Long-term durability of responses to 2 or 3 doses of hepatitis a vaccination in human immunodeficiency virus\u2013positive adults on antiretroviral therapy","volume":"215","author":"Cheng","year":"2017","journal-title":"J Infect Dis"}],"container-title":["Journal of Travel Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jtm\/advance-article-pdf\/doi\/10.1093\/jtm\/taae125\/59460909\/taae125.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jtm\/article-pdf\/32\/2\/taae125\/59460909\/taae125.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jtm\/article-pdf\/32\/2\/taae125\/59460909\/taae125.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T05:24:49Z","timestamp":1741757089000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jtm\/article\/doi\/10.1093\/jtm\/taae125\/7755368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":47,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,9,11]]},"published-print":{"date-parts":[[2025,3,11]]}},"URL":"https:\/\/doi.org\/10.1093\/jtm\/taae125","relation":{},"ISSN":["1195-1982","1708-8305"],"issn-type":[{"value":"1195-1982","type":"print"},{"value":"1708-8305","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,9,11]]},"article-number":"taae125"}}